Bio-Techne (NASDAQ:TECH) Shares Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on April 9th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/29/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Dayforce (NYSE:DAY) on 4/28/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/24/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of IDEXX Laboratories (NASDAQ:IDXX) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 4/9/2025.

Bio-Techne Stock Performance

Shares of TECH opened at $49.80 on Tuesday. The firm has a market capitalization of $7.87 billion, a P/E ratio of 50.30, a PEG ratio of 2.88 and a beta of 1.46. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.94 and a quick ratio of 2.77. Bio-Techne Co. has a one year low of $46.01 and a one year high of $85.57. The business has a fifty day moving average of $55.64 and a 200 day moving average of $66.78.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. As a group, sell-side analysts anticipate that Bio-Techne Co. will post 1.67 EPS for the current year.

Bio-Techne Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were issued a dividend of $0.08 per share. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.64%. Bio-Techne’s payout ratio is 32.32%.

Insider Transactions at Bio-Techne

In other news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares of the company’s stock, valued at $130,336.96. This trade represents a 48.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on TECH shares. KeyCorp reissued a “sector weight” rating on shares of Bio-Techne in a report on Wednesday, April 9th. Baird R W lowered shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Citigroup lowered their price target on shares of Bio-Techne from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Royal Bank of Canada raised their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 6th. Finally, StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Thursday, April 17th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $81.14.

Institutional Trading of Bio-Techne

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. World Investment Advisors LLC lifted its position in shares of Bio-Techne by 4.8% in the third quarter. World Investment Advisors LLC now owns 21,957 shares of the biotechnology company’s stock worth $1,755,000 after buying an additional 1,000 shares in the last quarter. Wilmington Savings Fund Society FSB grew its holdings in shares of Bio-Techne by 55.3% in the third quarter. Wilmington Savings Fund Society FSB now owns 4,651 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 1,656 shares in the last quarter. Tidal Investments LLC increased its position in Bio-Techne by 17.7% in the third quarter. Tidal Investments LLC now owns 28,940 shares of the biotechnology company’s stock worth $2,313,000 after purchasing an additional 4,356 shares during the last quarter. Synovus Financial Corp lifted its position in Bio-Techne by 1.5% during the third quarter. Synovus Financial Corp now owns 13,223 shares of the biotechnology company’s stock valued at $1,057,000 after purchasing an additional 198 shares during the last quarter. Finally, Oddo BHF Asset Management Sas purchased a new position in shares of Bio-Techne in the 3rd quarter worth $1,188,000. 98.95% of the stock is currently owned by institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.